Amicus eyes Pompe approval; Atea ends Dengue work; 2seventy, Travere line up offerings
Amicus Therapeutics began March with word that the FDA has scheduled a pre-approval inspection of its potential treatment for Pompe disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
